Rare disease patients in India are rarely involved in international orphan drug trials.
We wished to determine whether rare diseases patients from India had been enrolled in international trials to develop novel orphan drugs. There are two reasons to be interested in this. (a) Different ethnic or racial groups may respond differently to a particular drug. India has huge ethnic diversit...
Main Authors: | Monoswi Chakraborty, Mohua Chakraborty Choudhury, Indraneel Chakraborty, Gayatri Saberwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLOS Global Public Health |
Online Access: | https://doi.org/10.1371/journal.pgph.0000890 |
Similar Items
-
Rare disease patients in India are rarely involved in international orphan drug trials
by: Monoswi Chakraborty, et al.
Published: (2022-01-01) -
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01) -
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data.
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01) -
The role of patient organizations in the rare disease ecosystem in India: an interview based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-05-01) -
Facilitating audits of clinical trial data using documents of the Food and Drug Administration
by: Gayatri Saberwal, et al.
Published: (2022-12-01)